Private Advisor Group’s BioLineRX BLRX Stock Holding History

Private Advisor Group’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-25	Closed	-$15K	–	1124
2016 Q1	$15K	Buy	+25	New	+$15.7K	﹤0.01%	1017

Other funds holding BLRX

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Private Advisor Group's BLRX Position: Q2 2016 in Review

Private Advisor Group sold out of BioLineRX (BLRX) in Q2 2016, closing a stake of 25 shares — an estimated $15K sold.

Private Advisor Group first reported a position in BLRX in Q1 2016 and held it in 1 quarter. The position peaked at $15K in Q1 2016. 24 funds tracked by Wall St. Rank hold BLRX as of Q2 2016.

Private Advisor Group reported no remaining BioLineRX position as of Q2 2016 after selling out during the quarter.
Private Advisor Group sold 25 BioLineRX shares in Q2 2016, an estimated $15K.
Private Advisor Group first reported a position in BioLineRX in Q1 2016 and held it in 1 quarter.
Private Advisor Group's BioLineRX position peaked at $15K in Q1 2016.
24 funds tracked by Wall St. Rank held BioLineRX as of Q2 2016.

Based on Private Advisor Group's 13F filing for Q2 2016, filed 9 Aug 2016.